Melanotan II is widely recognized for tanning and appearance-related effects, giving it unusually strong consumer awareness.
FDA identifies published serious adverse-event case reports, and online availability does not establish quality, legality, or safety.
What a visitor should know.
Technical details: aliases, tracked claims, and data record
2 names in this peptide family.
Melanotan II and MT-II resolve to one record. Case reports are classified as safety signals, not efficacy evidence.
5 evidence questions.
Human benefitHuman safety reports onlyDoes Melanotan II have established human clinical benefit for uses to be specified in forthcoming meeting materials?
FDA approvalNo FDA approval identifiedIs Melanotan II FDA approved?
503A statusRegulatory recordIs Melanotan II on FDA's final 503A Bulks List or generally permitted because of committee activity?
Identity transferIdentity-sensitiveAre every product, alias, form, and related compound labeled Melanotan II automatically interchangeable?
See every Melanotan II evidence question →Open the machine-readable record ↗FDA placed the meeting before the end of February 2027
Melanotan II remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
The review has a public time window.
No committee recommendation or FDA decision has occurred.
How the FDA record developed.
This timeline separates early nominations and scientific reviews from committee votes and final FDA decisions.
FDA placed the meeting before the end of February 2027
Melanotan II remains one of five substances on the agenda. FDA has not yet posted the exact meeting date or compound-specific briefing materials.
Read the source ↗FDA announced a future advisory review
Melanotan II was named among five bulk drug substances scheduled for committee consideration.
Read the source ↗What has actually been studied?
Human studies appear on the left. Animal, cell, and laboratory studies appear on the right because they cannot establish that a treatment works in people.
FDA says the advisory review will happen before the end of February 2027 and identifies published serious adverse-event case reports.
Read the FDA review ↗Three healthy men received Melanotan II in an early dose-escalation study. Pigmentation occurred, along with nausea, fatigue, yawning, and prolonged erections; the sample was far too small to establish safety.
Read the study on PubMed ↗A case report described systemic toxicity, rhabdomyolysis, and kidney dysfunction after Melanotan II use. A case report cannot estimate how often an event occurs, but it is a meaningful safety signal.
Read the study on PubMed ↗Preclinical evidence will be classified when FDA posts the meeting briefing materials.
Important unknowns.
- FDA has identified limited or absent human safety information for the nominated use context.
- Peptide impurities, aggregation, immunogenicity, or API characterization may be material concerns.
- Compound-specific FDA concerns are linked in the source record.
These are evidence and regulatory uncertainties, not an individualized assessment of whether a treatment is appropriate.
Read the original sources.
Technical change history and comparison data
2 dated changes. 1 comparison groups.
These records show what each source added and whether it changed Peplyst's public conclusion.